top of page


FDA approves Sanofi's Infilbray as first treatment for neurological symptoms of type 3 Gaucher disease
Sanofi's oral glucosylceramide synthase inhibitor becomes the first FDA-approved medicine specifically targeting neurological symptoms of type 3 Gaucher disease, following evidence from a 52-week randomised study.

nuaxia
3 days ago2 min read


Italfarmaco licenses JCR's Phase III Hunter syndrome therapy JR-141 across US, Europe and Latin America
Italfarmaco has licensed JCR Pharmaceuticals' Phase III Hunter syndrome therapy JR-141 across the US, Europe and Latin America.

nuaxia
Oct 72 min read
bottom of page